Lauder Scott 4
4 · Gemini Therapeutics, Inc. /DE · Filed Feb 25, 2021
Insider Transaction Report
Form 4
Lauder Scott
Chief Technology Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-23+272,615→ 272,615 totalExercise: $14.21Exp: 2031-02-22→ Common Stock (272,615 underlying)
Footnotes (1)
- [F1]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 23, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.